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918Objective: Human atrial natriuretic peptide has recently become known not only as a heart failure drug but also
for myocardial protection. We investigated its direct myocardial protective effect on ischemia–reperfusion injury
in cardiac surgery.
Methods: Male pigs (35–45 kg) undergoing surgery with cardiopulmonary bypass, with 60-minute reperfusion
after 30-minute cardioplegia, were grouped by timing of atrial natriuretic peptide administration: group C (n¼ 8),
no atrial natriuretic peptide (cardioplegia only); group H1 (n¼ 8); 100-mg atrial natriuretic peptide administration
after aortic crossclamping; group H2 (n ¼ 8), administration before aortic declamping; and group H1þ H2
(n ¼ 8), administration both after crossclamping and before declamping. Blood and myocardial cyclic guanosine
monophosphate, calcium, and residual adenosine triphosphate levels were determined. Histologic investigation
was conducted by electron and optical microscopy.
Results: Atrial natriuretic peptide increased blood and myocardial cyclic guanosine monophosphate levels
(P<.0001, P<.0001, P<.007 H1þH2 vs C; P< .0014, P< .0007, P< .003 H1 vs C), decreased myocardial
calcium (P < .0038 H1 þ H2 vs C), and increased myocardial residual adenosine triphosphate. Electron
microscopy revealed ischemic changes in mitochondria and nuclei in group C but not in treatment groups.
Conclusions: Ischemia–reperfusion injury was inhibited with equal effectiveness by atrial natriuretic peptide
both during ischemia and immediately before reperfusion, acting directly on myocardium through cyclic guano-
sine monophosphate. Atrial natriuretic peptide may be useful as a supportive measure for patients with long aortic
crossclamping time or difficulties in weaning from cardiopulmonary bypass. (J Thorac Cardiovasc Surg
2010;139:918-25)Atrial natriuretic peptide (ANP) was isolated and identified
in 1984 by Kangawa and Matsuo.1 It is predominantly
synthesized in the atrium and involved in the regulation of
body fluid and circulation. A human atrial natriuretic peptide
(hANP) preparation, carperitide, was developed and has
been used mainly for treatment of heart failure because it
improves preload and afterload by diuresis2,3 and vasodila-
tation.4-6 In the past 25 years, studies have revealed the
role of ANP in cardiovascular endocrinologic systems and
elucidated the details of its metabolism. It has been demon-
strated to exert various effects, including inhibition of renin–
angiotensin, myocardial hypertrophy, and fibrosis.7-11
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The Journal of Thoracic and Cardiovascular Surgdisadvantages of cardiopulmonary bypass (CPB), which
include such complications as decreased urinary output
and third-space fluid shift, by administering an intravenous
infusion of ANP at a low dose (0.02–0.05 g) when CPB
was commenced.12 In addition, it has been recognized that
ANP decreases the demand for furosemide and inhibits
loss of potassium, deterioration in electrolyte balance, and
development of arrhythmias during unstable conditions after
surgery.13,14 ANP has become a useful drug for periopera-
tive and postoperative management in our department.
Recent studies demonstrated that ANP exerts various
actions. It has been reported that ANP inhibits volume over-
load–related factors and vasopressive factors (sympathetic
nervous system, renin–angiotensin system, endothelin-1,
inflammatory cytokines, tumor necrosis factor a, and inter-
leukin 6) referred to as cardiotoxic factors.15,16 It has also
been reported that ANP exerts coronary vasodilatation
when administered into the coronary artery during percuta-
neous transluminal coronary angioplasty and inhibits
myocardial remodeling in remote areas afterward.17 These
studies suggest that ANP exerts myocardial protection.
It has also been demonstrated at our institution that ANP
inhibits ischemia–reperfusion injury by inhibition of an
increase in myocardial calcium concentration. In addition,
our institution has already reported that intracoronary
administration of ANP to pig hearts as an adjuvant toery c April 2010
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Dcardioplegia increases myocardial cyclic guanidine mono-
phosphate (cGMP) level after reperfusion and decreases
myocardial calcium level, leading to relief of ischemia–
reperfusion injury. This indicates a potential of direct
myocardial protective effect of ANP.18
This study aimed to reveal the detailed mechanism of
direct myocardial protective effect of ANP by comparing
timing variations of ANP administration.
MATERIALS AND METHODS
Thirty-two male pigs (weight 40.82.7 kg) were used for the experi-
ments. All animals received humane care in accordance with the ‘‘Principles
of Laboratory Animal Care’’ and the ‘‘Guide for the Care and Use of
Laboratory Animals’’ (www.nap.edu/catalog/5140.html). An arterial line
was established into the right common carotid artery and a thermodilution
catheter was introduced into the right external jugular vein for monitoring
of arterial pressure, central venous pressure, and pulmonary arterial
pressure. Limb-lead electrocardiography was also monitored. After endotra-
cheal intubation, animals were ventilated with a tidal volume of 10 to 15
mL/kg and a rate of 20 to 25 breaths/min with a respirator (Servo 900E;
Siemens-Elema AB, Solna, Sweden) maintaining percutaneous oxygen sat-
uration at 95% to 100%. A catheter (CX-654U; Cathex Co, Ltd, Tokyo,
Japan) was placed in the coronary sinus through the left internal jugular
vein for blood collection. The thorax was opened by median sternotomy.
A cannula (TF-024L; Edwards Lifesciences Research Medical, Midvale,
Utah) was inserted into the right atrium for the inferior vena cava, and
another cannula (A211-5.2; Stockert Instrumente GmbH, Munich, Ger-
many) was inserted into the ascending aorta for blood perfusion. The
CPB was prepared with a gyropump (Kyocera Corp, Kyoto, Japan) and
an oxygenator (HPO-20H-C; Senko Ika Kogyo [Mera], Tokyo, Japan). In
addition, a cannula (Medtronic, Inc, Minneapolis, Minn) was inserted into
the aortic root for perfusion of a cardioplegic solution and venting. CPB
was started at 37C. After the ascending aorta was clamped, a cold (4C)
cardioplegic solution (Miotecter; Mochida Pharmaceutical Co, Ltd, Tokyo,
Japan) was infused (20 mL/kg) through the cannula inserted into the aortic
root to achieve cardioplegic arrest for 30 minutes. Thereafter, the aortic
clamping was released and reperfusion started. After reperfusion was con-
tinued for 60 minutes, animals were weaned from CPB (Figure 1).
Experimental Groups
Animals were divided into 4 groups according to the timing of ANP
infusion: the control group (group C) consisted of 8 animals treated only
with a cardioplegic solution (Miotecter) after clamping of the ascending
aorta; the postclamping group (group H1) consisted of 8 animals treated
with ANP at a dose of 100 mg followed by Miotecter after aortic
crossclamping; the predeclamping group (group H2) consisted of 8 animals
treated with ANP at a dose of 100 mg before aortic declamping; and the com-
bined group (group H1þH2) consisted of 8 animals treated with ANP at
a dose of 100 mg timed both after aortic crossclamping and before aortic
declamping (Figure 1).The Journal of Thoracic and CaANP Administration Method
The hANP was bolus infused into the aorta near the cardioplegic aorta
cannula with a syringe with a 27-gauge needle.
Specimen Collection Method
Blood specimens were collected from the catheter placed in the coronary
sinus at 4 time points: before the CPB (pre-CPB), immediately after aortic
declamping (start reperfusion), 30 minutes after the start of reperfusion
(reperfusion 30 min), and after the completion of reperfusion (post-CPB;
Figure 1). In the collected blood specimens, cGMP was measured. For
determination of myocardial calcium, cGMP, and residual adenosine
triphosphate (ATP) levels, specimens of the myocardium were collected
after the completion of reperfusion by cutting off the muscle around the
diagonal branch; the myocardium was isolated from the inside of the inner
membrane (Figure 1). A portion of each specimen was immediately frozen
with liquid nitrogen. After 0.1-N hydrochloric acid cooled in ice was added
to the frozen specimen, the myocardial specimen was homogenized. The
homogenate was centrifuged at 13,000 rpm and 4C for 40 minutes, and
the supernatant was used as a sample for determination of myocardial
calcium, cGMP, and residual ATP levels. Calcium concentration was
measured by atomic absorption spectrophotometry with a Hitachi Z-6100
analyzer (Hitachi, Ltd, Tokyo, Japan); cGMP concentration was measured
with a YAMASA Cyclic GMP Assay Kit (Yamasa Corp, Chiba, Japan); and
ATP was measured by the firefly luciferin–luciferase method with
a KIKKOMAN ATP assay kit (KIKKOMAN, Ltd, Tokyo, Japan).
Electron Microscopic Observation Method
Another portion of each specimen was examined microscopically. For
microscopy, the specimen was fixed with a 2.5% glutaraldehyde fixative
at 4C for 12 hours. After that, it was dehydrated in ethanol and then pro-
pylene oxide, and embedded in Quetol 812 (Nissin EM Co, Ltd, Tokyo,
Japan). The embedded specimen was sectioned with an Ultracut UCT ultra-
microtome (Leica Microsystems, Vienna, Austria) to prepare semiultrathin
sections and ultrathin sections.
Optimal Microscopic Observation Method of
Myocardial Ischemic Changes
The semiultrathin sections were stained with toluidine blue and observed
with a light microscope to examine nuclear chromatin in myocardial cells.
Nuclear chromatin was classified into 4 grades, as specified in Figure 7,
and ischemic changes were assessed quantitatively according to the chroma-
tin count in each treatment group. The ultrathin sections were double stained
with uranyl acetate and lead citrate and observed with an electron micro-
scope (JEM 1200EX; JEOL Ltd, Tokyo, Japan).
All microscopic examinations were performed by observers blinded to
ANP treatment group.
Statistics
The experimental results were expressed as meanSD. The paired t test
and 1-factor analysis of variance were applied to test statistical significance
of differences. When a value was determined to be significant by 1-factor
analysis of variance, the Scheffe´ method was used to analyze the
relationship further.
RESULTS
Hemodynamics
No significant differences in aortic pressure were
observed among the 4 groups either before CPB (103.9 
19.1 mm Hg for group H1, 100.9  19.6 mm Hg for group
H2, 97.9 17.6 mm Hg for group H1þH2, 98.4 23.1 mm
Hg for group C) or after CPB (84.3 11.5 mm Hg for grouprdiovascular Surgery c Volume 139, Number 4 919
FIGURE 1. Experimental method and groups. Thirty-two pigs underwent surgery with cardiopulmonary bypass (CPB) and were divided into 4 groups
according to timing of atrial natriuretic peptide (ANP) administration. In group C (n ¼ 8), there was no use of atrial natriuretic peptide after aortic (Ao) cross-
clamping; only cardioplegia (Miotecter; Mochida Pharmaceutical Co, Ltd, Tokyo, Japan) was used. After 30 minutes of cardioplegia, reperfusion was
performed for 60 minutes. In group H1 (n ¼ 8), atrial natriuretic peptide (100 mg) was administered after aortic crossclamping through ascending aorta.
In group H2 (n¼ 8), atrial natriuretic peptide was administered before aortic declamping. In group H1þH2 (n¼ 8), atrial natriuretic protein was administered
both after aortic crossclamping and before aortic declamping.
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DH1, 79.1  3.5 mm Hg for group H2, 83.1  4.5 mm Hg for
group H1þH2, 80.4  10.1 mm Hg for group C). Rectal
temperatures of pigs before aortic crossclamping were
36.3C  0.5C for group C, 36.1C  0.6C for group
H1, 35.8C  0.6C for group H2, and 36.2C  0.8C
for group H1þH2. There were no significant differences
among the groups. Myocardial temperatures before aorticFIGURE 2. Blood cyclic guanosine monophosphate (cGMP) concentra-
tions. Concentrations were significantly increased in groups H1þH2 and
H2 relative to group C. *1 indicates P< .0001 group H1þH2 versus C;
*2 indicates P<.0001 group H1þH2 versus C; *3 indicates P<.007 group
H1þH2 versus C; *4 indicates P< .0014 group H2 versus C; *5 indicates
P<.0007 group H2 versus C; *6 indicates P<.003 group H2 versus C; *7
indicates P<.0138 group H1þH2 versus H1; *8 indicates P<.0294 group
H1þH2 versus H1; *9 indicates P< .0424 group H1 versus H2.
920 The Journal of Thoracic and Cardiovascular Surgdeclamping were 18.3C  0.9C for group C, 19.1C 
0.6C for group H1, 19.6C  0.6C for group H2, and
18.2C  0.5C for group H1 þ H2. There were no
significant differences among the groups.Blood Chemistry
Blood cGMP concentrations were significantly increased
in groups H1 þ H2 and H2 relative to those in group C.
In group H1þH2, concentrations were 135.6  51.6 pmol/
mL at the start of reperfusion (P< .0001), 85.8  20.2FIGURE 3. Residual myocardial adenosine triphosphate (ATP) levels. No
significant differences were observed among treatment groups (H1, H2, H1
þH2); however, residual adenosine triphosphate level tended to increase in
groups H1, H2, and H1þH2 relative to group C.
ery c April 2010
FIGURE 4. Myocardial cyclic guanosine monophosphate (cGMP)
concentrations. Concentration was significantly increased in groups H2
and H1þH2 relative to group C. *1 indicates P< .0001 H1þH2 versus
C; *2 indicates P< .0001 H1þH2 versus H1; *3 indicates P< .0001 H2
versus C; *4 indicates P< .0001 H2 versus H1. wg, Wet weight in grams.
FIGURE 5. Myocardial calcium (Ca) concentration. Increase in concen-
tration was significantly inhibited in group H1þH2 relative to group C.
*1 indicates P< .0038 H1þH2 versus C. wetg, Wet weight in grams.
Wakui et al Acquired Cardiovascular Disease
A
C
Dpmol/mL at 30 minutes of reperfusion (P<.0001), and 57.0
 3.2 pmol/mL after CPB (P<.0007). In group H2, concen-
trations were 115.5  56.4 pmol/mL at the start of
reperfusion (P<.0014), 77.8 27.8 pmol/mL after 30 min-
utes of reperfusion (P< .0007), and 58.4  11.4 pmol/mL
after CPB (P < .0003). No significant differences were
observed between groups H1 and C, although cGMP
concentrations showed a tendency toward increasing in
group H1 (Figure 2).Residual Tissue ATP Levels
No significant differences in residual ATP level were
observed among groups H1, H2, and H1þH2. There was,
however, a tendency toward increased residual ATP in
groups H1, H2, and H1þH2 relative to group C: 89.36 
22.6 mmol/L for group H1 (P < .0587), 84.90  16.4
mmol/L for group H2 (P< .1476), and 89.73  19.4 mmol/
L for group H1 þ H2 (P< .0540) versus 62.91  13.4
mmol/L for group C (Figure 3).Tissue cGMP Concentrations
The myocardial cGMP concentrations were significantly
increased in groups H2 and H1þH2 relative to group C:
20.98  3.17 pmol/g wet weight for group H2 (P< .0001)
and 19.35  2.39 pmol/g wet weight for group H1þH2
(P< .0001) versus 8.23  4.16 pmol/g wt weight for group
C (Figure 4).Tissue Calcium Concentrations
ANP inhibited an increase in calcium concentration:
0.0406  0.006 mg/g wet weight for group H1þH2 versus
0.070  0.020 mg/g wet weight for group C (P< .0038;
Figure 5). In the other ANP treatment groups (H1 and
H2), there was no significant difference; however, a tendencyThe Journal of Thoracic and Cawas observed toward inhibition of calcium increase: 0.052
0.012 mg/g wet weight for group H1 (P< .1035) and 0.056
 0.017 mg/g wet weight for group H2 (P< .2673). It was
predicted that calcium increase would be most inhibited in
group H2, which showed the highest concentration of tissue
cGMP, but it was actually inhibited more in group H1.Electron Microscopic Images
Mitochondria. Swelling of mitochondria with sparse cris-
tae was observed in group C. In contrast, normal mitochon-
dria were preserved and large amounts of glycogen granules
were seen in the ANP treatment groups (Figure 6, A).
Myocardial fibers. Large numbers of thick and fuzzy
contraction bands were observed in group C. In contrast,
normal distinct myocardial fibers were preserved in the
ANP treatment groups (Figure 6, B).
Myocardial nuclei. Aggregates of nuclear chromatin or
aggregations of chromatin around the nuclei were markedly
observed in group C. These changes were minor in the ANP
treatment groups, however, with the nuclei equivalent to
those in nonischemic myocardium (Figure 6, C).
Electron microscopy revealed a remarkable difference
between each of the 3 ANP groups and the control group.
It was impossible, however, to determine any differences
among the 3 ANP groups.Toluidine Blue Images
Ischemic changes in nuclear chromatin were seen on
toluidine blue–stained images. In group C (n ¼ 8), the
incidence of mild ischemic change was 44% (232/522). In
contrast, the incidences of normal myocardium in group
H1 (n ¼ 8), group H2 (n ¼ 8), and group H1þH2 (n ¼ 8)
were 57.1% (285/499), 53.3% (279/523), and 64.0%
(264/413), respectively, and ischemic changes were
inhibited in the ANP treatment groups. Because all 4 groups
were treated with a cardioplegic solution, the incidence of
irreversible ischemic change was 0% (Figure 7).rdiovascular Surgery c Volume 139, Number 4 921
FIGURE 6. Electron microscopic images. A, Mitochondria in electron microscopy. Swelling of mitochondria with sparse cristae was observed in group C. In
contrast, normal mitochondria were preserved and large amounts of glycogen granules were seen in human atrial natriuretic peptide (hANP) treatment groups.
B, Myocardial fibers in electron microscopy. Large numbers of thick, fuzzy contraction bands were observed in group C. In contrast, normal distinct myo-
cardial fibers were preserved in treatment groups. C, Myocardial nuclei in electron microscopy. Aggregates of nuclear chromatin or aggregation of chromatin
around nuclei were markedly observed in group C; however, these changes were minor in groups, with nuclei equivalent to those in nonischemic myocardium.
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DDISCUSSION
In recent years, studies on myocardial protection by ANP
have been occasionally reported. These studies have not
investigated direct effects of ANP on the myocardium. In
most of the studies, the myocardial protection was likely
a secondary effect of inhibition of cardiotoxic factors or
coronary vasodilatation. In our study, we directly adminis-
tered hANP into the pig coronary artery, and blood speci-
mens were collected from a catheter inserted into the
coronary sinus. Myocardial tissue specimens were also
collected to investigate direct effects of ANP on the
myocardium.
Kitakaze and colleagues19 reported an experiment
conducted with a dog ischemia–reperfusion model. The
model was prepared by clamping the left anterior descending
coronary artery for 90 minutes, followed by reperfusion for
6 hours. The animals received carperitide at 0.1 mg/(kg min)
continuously from immediately before reperfusion until
1 hour after reperfusion. They reported that this treatment
produced a significant reduction in myocardial infarct and
risk areas and an improvement in cardiac function 1 month
after. In addition, J-WIND,19 a large clinical trial, reported
similar results: carperitide in patients with myocardial
infarction reduced the infarct size by 14.7%, increased left
ventricular ejection fraction in the chronic stage by 5.1%,
and decreased reperfusion injury by 25.9%. These reports
strongly suggest the possibility of an inhibitory effect of
ANP on ischemia–reperfusion injury.922 The Journal of Thoracic and Cardiovascular SurgIn both reports, however, the timing of ANP administra-
tion was after reperfusion or immediately before reperfu-
sion. In contrast, ANP administration in our experiments
was begun immediately after ischemia. Naturally, in the
J-WIND study of patients with acute myocardial infarction,
it was impossible to administer ANP either before or during
cardiac ischemia. In clinical situations, ANP can be admin-
istered before the onset of ischemia only during cardiac
surgical procedures.
We investigated the effects of ANP on ischemia–
reperfusion injury associated with cardiac surgery by using
an experimental model designed to include aortic cross-
clamping, cardioplegic arrest, aortic declamping, and reper-
fusion. It is a widely accepted that the potential
mechanisms of development of the stunned myocardium
are that calcium overload and presence of free radicals
may play a role.20 It has been reported that vasodilators
such as nitric oxide, carbon monoxide, and natriuretic pep-
tides inhibit an increase in calcium ion concentrations in
the vascular smooth muscle by using cGMP as the second
messenger.21-23 In our study, myocardial and blood cGMP
concentrations were increased after administration of ANP
in the ischemic condition, and myocardial calcium concen-
trations were significantly decreased during reperfusion.
We therefore believe that ANP directly acts on the myocar-
dium and inhibits calcium overload through cGMP to im-
prove the stunned myocardium. From the results of this
study, we presume that ANP synthesizes cGMP even inery c April 2010
FIGURE 7. Nuclear chromatin grades and ischemic changes in nuclear chromatin. Nuclear chromatin in myocardial cells were observed with light micros-
copy and classified according to 4 grades: normal (), slight ischemia (þ), hyperischemia (þþ), irreversible ischemia (þþþ). Ischemic changes were inhibited in
treatment groups (H1þH2 more so than H1 and H2). All 4 groups were treated with cardioplegic solution, so incidence of irreversible ischemic change was 0%.
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Dpig cardiac myocytes and that this synthesis inhibits an in-
crease in calcium ion concentration. Electron microscopy
showed that mitochondria and myocardial fibers were pre-
served, whereas abnormal changes in nuclear chromatin
were inhibited. These findings are considered to reflect
inhibition of ischemia–reperfusion injury (calcium ion
overload) by the various effects of cGMP. Because mito-
chondria were preserved, production of ATP was
maintained. The residual myocardial ATP may have
increased because of decrease in the amount of ATP used
for excretion of calcium.
In a previous study,18 the timing of ANP administration
was only after aortic crossclamping. In light of the hypothe-
sis that ischemia–reperfusion injury might occur during
reperfusion, it was expected in this experiment that more
inhibitory effect on myocardial calcium overload would be
obtained by changing the timing of ANP administration
from immediately after ischemia (group H1) to immediately
before reperfusion (group H2). Calcium concentration
tended to decrease to a greater extent in group H1 than in
group H2, however, with an increase in the concentrationThe Journal of Thoracic and Caof myocardial cGMP (there was no significant difference,
but it showed tendency to decrease with ANP, H1
P<.1035 vs C and H2 P<.2673 vs C). The higher myocar-
dial cGMP concentration in group H2 can be attributed to the
fact that the delay between ANP administration and cardiac
muscle extraction was shorter in this group than in group H1.
The calcium concentration decreased more significantly in
group H1 þ H2 than in group H2. In addition, calcium
concentration decreased to a greater extent in group H2
than in group H1, although the difference was not signifi-
cant. The possibility that the H1 group treatment is more ef-
fective than H2 group cannot be denied. In an investigation
by Marban and associates,20 time-related change in calcium
concentration during ischemia–reperfusion was measured
with Langendorff ferret heart models. As shown in Figure 8,
calcium increase was observed more remarkably before
reperfusion (during ischemia) than immediately after reper-
fusion, defying our expectations; calcium increase immedi-
ately after reperfusion was mild, and then calcium
concentration decreased. This indicates that myocardial
calcium increase occurred mainly during ischemia. Thus tordiovascular Surgery c Volume 139, Number 4 923
FIGURE 8. Time course of changes in calcium (Ca) concentration ([Ca], [Ca2þ]) during ischemia–reperfusion. Increase in calcium was more remarkable
before reperfusion (during ischemia, 1) than immediately after reperfusion (2), contrary to our expectations. There was slight increase immediately after re-
perfusion, and then levels decreased. Thus myocardial calcium increase occurred mainly during ischemia. Data from Marban and associates.20 ANP, Atrial
natriuretic peptide.
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ANP administration during ischemia may be more effective
than before reperfusion. This may be why calcium concen-
tration decreased more in group H1 than in group H2.
This experiment was designed with an eye to clinical
application in cardiac surgery, and cardioplegia was there-
fore used in all animals. To investigate the effect of ANP
alone on ischemia–reperfusion injury, an investigation is
desired in which aortic crossclamping time is prolonged
without cardioplegia. Although left ventricular function
was not measured in this study, ANP was shown to be
effective in the protection of cardiac muscle. We plan to
investigate the effect of ANP on left ventricular function
in the future.
On the basis of the satisfactory results of this experi-
ment, the clinical application was approved by the ethical
review board of Nihon University Itabashi Hospital and
has already started as ‘‘hANP shot.’’ Thus far we have
obtained satisfactory results. ANP is expected to be used
as supportive therapy for patients with long aortic
crossclamping times or those with difficulties in weaning
from CPB.CONCLUSIONS
ANP acts directly on the myocardium through cGMP.
ANP inhibits ischemia–reperfusion injury by decreasing
myocardial calcium concentration. Ischemia–reperfusion
injury is inhibited with equal effectiveness when adminis-
tered either during ischemia or immediately before
reperfusion.924 The Journal of Thoracic and Cardiovascular SurgReferences
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